---
title: "Kyntra Bio Highlights Pipeline Progress in Prostate Cancer and Anemia Therapies in New Corporate Presentation"
description: "Kyntra Bio Inc. has updated its corporate activities and clinical programs, including the sale of FibroGen China to AstraZeneca for $220 million and repayment of its term loan, extending its cash runw"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273131112.md"
published_at: "2026-01-20T21:05:08.000Z"
---

# Kyntra Bio Highlights Pipeline Progress in Prostate Cancer and Anemia Therapies in New Corporate Presentation

> Kyntra Bio Inc. has updated its corporate activities and clinical programs, including the sale of FibroGen China to AstraZeneca for $220 million and repayment of its term loan, extending its cash runway to 2028. The company initiated a Phase 2 trial for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer, with interim results expected in late 2026. Kyntra Bio aims to address the unmet need for new treatments in late-stage prostate cancer with its targeted therapies, including YS5FL, a monoclonal antibody targeting CD46.

Kyntra Bio Inc. has provided an update on its recent corporate activities and clinical development programs. The company completed the sale of FibroGen China to AstraZeneca for approximately $220 million and repaid its term loan to Morgan Stanley Tactical Value. These actions have extended the company’s cash runway into 2028. Kyntra Bio highlighted progress with its oncology pipeline, including the initiation of a Phase 2 trial for FG-3246, a CD46-targeting antibody-drug conjugate (ADC), and FG-3180, a PET imaging agent, in metastatic castration-resistant prostate cancer (mCRPC). Interim results from this trial are expected in the second half of 2026. The presentation also noted the high unmet need for new treatment options in late-stage prostate cancer and described YS5FL, a fully-human monoclonal antibody targeting CD46, as part of its approach to developing more targeted therapies for mCRPC. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [KYNB.US - Kyntra Bio](https://longbridge.com/en/quote/KYNB.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX | NEOS Investment Management LLC has reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 61.6% in Q3, no | [Link](https://longbridge.com/en/news/276532688.md) |
| Bristol-Myers Says Reblozyl Treatment Shows Significant Improvement in Thalassemia Patients | Bristol-Myers Says Reblozyl Treatment Shows Significant Improvement in Thalassemia Patients | [Link](https://longbridge.com/en/news/276600903.md) |
| Cipla Supply Partner's Greece Facility Gets OAI Classification from US FDA | Cipla Supply Partner's Greece Facility Gets OAI Classification from US FDA | [Link](https://longbridge.com/en/news/276586653.md) |
| FDA Gives Green Light to AstraZeneca's All-Oral Calquence-Venetoclax Combo for CLL | The FDA has approved AstraZeneca's all-oral treatment combining Calquence and venetoclax for chronic lymphocytic leukemi | [Link](https://longbridge.com/en/news/276597509.md) |
| AlzeCure Pharma Pain Project ACD440 Gets Orphan Drug Status In EU | AlzeCure Pharma AB :PAIN PROJECT ACD440 GRANTED ORPHAN DRUG STATUS IN THE EU | [Link](https://longbridge.com/en/news/276726632.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.